Journal article

Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol

Amber Weller, John Gleeson, Mario Alvarez-Jimenez, Patrick McGorry, Barnaby Nelson, Kelly Allott, Sarah Bendall, Cali Bartholomeusz, Peter Koval, Susy Harrigan, Brian O'Donoghue, Alex Fornito, Christos Pantelis, G Paul Amminger, Aswin Ratheesh, Andrea Polari, Stephen J Wood, Kristi van der El, Carli Ellinghaus, Jesse Gates Show all



Antipsychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive psychotic symptoms and a reduction in relapse rates. However, there has been little improvement in functional outcomes for people with psychosis. At the same time there is increasing evidence that medications contribute to life shortening metabolic and cardiovascular illnesses. There is also uncertainty as to the role played by antipsychotic medication in brain volume changes. AIM: The primary aim of the study is, in a population of young people with first-episode psychosis, to compare functional outcomes between an antipsychotic dose r..

View full abstract